<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Syngeneic Models: the Old Becoming New at AACR Shanghai

Following the success of the 2014 event, the American Association for Cancer Research (AACR) held a second edition of the New Horizons in Cancer Research Conference Series in China. As the previous year, the meeting highlighted the latest and most exciting discoveries in major areas of cancer research, and provided a unique opportunity for investigators from all over the world to meet, network, and build new scientific interactions.

A delegation of Crown Bioscience scientists, business development managers and marketers attended the event and reported back with great enthusiasm the latest findings around clinical trial design, drug resistance, hormone-related cancer and translational oncology.

Besides meeting clients and colleagues at Crown’s booth our scientists presented their data with seven posters covering topics such as the use of preclinical models to understand and overcome drug resistance, the generation of new models with a chimeric human-murine immune system for testing the efficacy of novel immunotherapeutic agents, the efficacy of a new tyrosine kinase inhibitor tested on a cohort of non-small cell lung cancer patient-derived xenograft (NSCLC-PDX) models, and the molecular characterization and genomic profiling of a panel of syngenic models.

Syngenic models are allograft of murine tumor cells in hosts from the same strain with a fully functional immune system. They were developed over 50 years ago as early in vivo models for oncology drug development. After an initial phase of great popularity they drifted out of the drug discovery landscape with the shift towards therapies directed against human targets, when they were replaced by in vivo models expressing human targets, such as genetically engineered mouse models (GEMM) or PDX.

Following the success of new immunotherapy agents (checkpoint inhibitors), syngeneic models have resumed center stage. Because they retain an intact immune system, they are considered particularly relevant models to study immunologically based therapies used either as single agents or in combination with other drugs that modulate the immune system’s ability to identify and destroy cancer cells.

With our greater understanding of the immunological makeup of the tumors and their responsiveness to checkpoint inhibitors, it has become clear that there is still a lot to learn. Beyond simply identifying syngeneic models as responder/non responder to immunotherapy, we are starting to ask how to best position these models for drug development and how can they help identify biomarkers of response in the patient population.

The group headed by Dr. Qian Shi at Crown Bioscience has summoned up their efforts to sequence and immuno-profile a panel of syngenic models in the attempt to discover biomarkers of response and to better inform the selection of models for immunotherapy studies.

On a panel of syngenic models, the group led by Dr. Shi tested the antitumor activity of the anti PD-1, PD-L1, and CTLA-4 antibodies, which by binding to these proteins on the surface of the tumor and immune cells, block the tumor dependent inhibition of the immune system. As reported in the study, some syngenic tumor models responded better than others.

All models were genetically profiled to identify a signature predictive of response to immunotherapy and tumors were screened for the presence of infiltrating immune cells. The investigators found a defined set of genes as potential predictive biomarkers of response. Moreover they discovered that the ratio between two subtypes of T cells (Teff/Treg) in the tumor microenvironment represents a good predictor of efficacy for the checkpoint inhibitors tested.

Crown Bioscience congratulates Dr. Shi and his group for winning the “best poster award” during this year AACR Shanghai for their work on the characterization and profiling of syngenic tumor models. At Crown we are committed to improving the selection of drug candidates by using the most clinically relevant models and services.

To talk to us about our syngenic models or for any other information about our immunotherapy research platforms email us today at busdev@crownbio.com.

Related Posts